Chapter 5
Nanoparticle technologies


The first described nanoscale drug delivery systems were lipid vesicles [94]. The first application of targeted liposomes was reported in 1980 [95]. Since then, research has led to important progress in the development of nanoparticles engineered to have multifunctional capabilities, as well as “smart” properties such as the ability to respond to the environment, to facilitate more effective drug delivery strategies. Nanoparticle technologies for nanomedicine include polymeric NPs, polymer-drug conjugates NPs, micelles, liposomes, metal complexes, carbon derivates, peptides NPs, silica NPs, quantum dots and dendrimers. The diversity of delivery systems allows nanoparticles to be developed with a diverse array of shapes, size, and components which enables them to be tailored for specific applications. However, the primary consideration when designing any drug delivery system is to achieve more effective therapies, by controlling the drug concentration in the therapeutic window, reducing cytotoxic effects, and improving patient compliance.

  • 5.1 Polymeric and polymer-drug conjugate nanoparticles
  • 5.2 Micelle nanoparticles
  • 5.3 Liposomes
  • 5.4 Gold and silver nanoparticles
  • 5.5 Metal oxide
  • 5.6 Magnetic nanoparticles
  • 5.7 Carbon nanotubes
  • 5.8 Fullerenes
  • 5.9 Peptides nanoparticles
  • 5.10 Silica nanoparticles
  • 5.11 Quantum dots
  • 5.12 Dendrimers

Related Content

Customize your page view by dragging and repositioning the boxes below.

Related Journal Articles
Related eBook Content
Topic Collections

Sorry! You do not have access to this content. For assistance or to subscribe, please contact us:

  • TELEPHONE: 1-800-843-2763 (Toll-free in the USA)
  • EMAIL: asmedigitalcollection@asme.org
Sign In